H. Yokota

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
H Yokota, H. Yokota, Harushige Yokota
Publication record
56 papers · 1,893 citations · H-index 21

PAPERS

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
20246 citationsauthor #6
A confirmatory trial of modified radical hysterectomy for patients with FIGO stage IB1 cervical cancer with tumor diameter preoperatively estimated at 2 cm or less: Japan Clinical Oncology Group study, JCOG1101.
20234 citationsauthor #9
Correction to: Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group
20221 citationsauthor #9
Regional differences in human papillomavirus type 52 prevalence among Japanese women with cervical intraepithelial neoplasia†.
20221 citationsauthor #6
Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women
20229 citationsauthor #5
Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group
20228 citationsauthor #9
Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.
2020191 citationsauthor #13
Avelumab in platinum-resistant/refractory ovarian cancer (PRROC): phase 3 results from JAVELIN Ovarian 200
20193 citationsauthor #9
Spread of tumour and adverse events after modified radical hysterectomy for FIGO Stage IB1 cervical cancer patients with tumour diameter preoperatively estimated 2 cm or less: Japan Clinical Oncology Group trial (JCOG1101); exploratory analysis before primary analysis
20190 citationsauthor #9
Application of deep learning to the classification of images from colposcopy
2018104 citationsauthor #7
A randomized phase II/III trial of conventional paclitaxel and carboplatin (cTC) versus dose-dense paclitaxel and carboplatin (ddTC), with or without bevacizumab (Bmab), for stage IVb, recurrent, or persistent cervical cancer (CC): Japan Clinical Oncology Group study (JCOG1311).
20182 citationsauthor #9
Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602.
201837 citationsauthor #13
Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).
201834 citationsauthor #5
Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer
201736 citationsauthor #3
Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients
201621 citationsauthor #22
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
2016228 citationsauthor #13
Introduction of Total Laparoscopic Hysterectomy at a Core Center for Cancer
20160 citationsauthor #6
Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour.
201527 citationsauthor #10
ISP-7-6 UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and nedaplatin : A Saitama tumor board (STB) study(Group 7 Oncology 7,IS Poster,International Session)
20150 citationsauthor #11
Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A).
201588 citationsauthor #18
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Cervical Adenocarcinoma
201445 citationsauthor #2
Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study.
201427 citationsauthor #4
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602.
201416 citationsauthor #15
UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study.
20135 citationsauthor #7
Octreotide Acetate Administration for Malignant Bowel Obstruction Induces Severe Bradycardia in Patients with Terminal Stage Cancer: Two Case Reports
20130 citationsauthor #7
ISP-14-1 Treatment patterns and prognosis of stage I-II node positive cervical cancer(Group 14 Oncology 5,IS Poster,International Session)
20130 citationsauthor #7
P2–106END OF LIFE CARE AT A GYNECOLOGIC ONCOLOGY UNIT
20130 citationsauthor #7
Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)
2013126 citationsauthor #9
Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)?
201355 citationsauthor #13
Treatment Patterns and Prognosis of Figo Stage IVB Cervical Cancer
20120 citationsauthor #7
[Treatment for adenocarcinoma and adenosquamous carcinoma of the uterine cervix].
20120 citationsauthor #1
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin (TC) Versus Paclitaxel Plus Cisplatin (TP) in Stage IVB or Recurrent Cervical Cancer: Japan Clinical Oncology Group Study (JCOG0505)
20129 citationsauthor #9
Clinicopathological prognostic factors and the role of cytoreduction in surgical stage IVb endometrial cancer: a retrospective multi-institutional analysis of 248 patients in Japan.
201233 citationsauthor #5
ISP-3-2 Treatment patterns and prognosis of stage 2b cervical cancer(Group 3 Oncology 3,IS Poster,International Session)
20120 citationsauthor #2
Is a Low Dose of Concomitant Chemotherapy With Extended-Field Radiotherapy Acceptable as an Efficient Treatment for Cervical Cancer Patients With Metastases to the Para-Aortic Lymph Nodes?
20118 citationsauthor #3
UGT1A1 genotype-based phase I study for recurrent and refractory gynecologic cancer patients treated with combination therapy of irinotecan and cisplatin (STB-06).
20110 citationsauthor #7
Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection.
2010185 citationsauthor #10
A pharmacogenetic UGT1A1 dose-escalation study for recurrent and refractory gynecologic cancer patients treated with combination therapy of irinotecan and cisplatin.
20090 citationsauthor #6
Clinical Significance of UDP-Glucuronosyltransferase 1A1*6 for Toxicities of Combination Chemotherapy with Irinotecan and Cisplatin in Gynecologic Cancers
200958 citationsauthor #8
Clinical significance of UDP-glucurosyltransferase 1A1*6 upon toxicities of combination chemotherapy of irinotecan and cisplatin in gynecologic cancers: A preliminary multi-institutional result
20080 citationsauthor #6
Spectral karyotyping and fluorescence in situ hybridization analyses identified a novel three-way translocation involving inversion 16 in therapy-related acute myeloid leukemia M4eo.
20087 citationsauthor #3
Differences in serum bisphenol a concentrations in premenopausal normal women and women with endometrial hyperplasia.
2004130 citationsauthor #7
A Case of Estrogen-Producing Brenner Tumor with a Stromal Component as a Potential Source for Estrogen
200215 citationsauthor #6
Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy.
1997166 citationsauthor #5
Successful treatment of brain metastases from ovarian cancer using gamma-knife radiosurgery.
199731 citationsauthor #3
Association of Multiple Human Papillomavirus Types with Vulvar Neoplasias
199640 citationsauthor #4
Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma: A proposal for essential sites for lymph node biopsy
1996114 citationsauthor #3
[Amplification and typing of human papillomavirus (HPV) DNA from female genitalia by polymerase chain reaction using a consensus primer].
19922 citationsauthor #1
Gynandroblastoma of the ovary having a typical morphological appearance: a case study.
19917 citationsauthor #4
Detection of Human Papillomavirus Types 6/11, 16 and 18 in Exfoliated Cells from the Uterine Cervices of Japanese Women with and without Lesions
199014 citationsauthor #1
[Retroperitoneal lymph node metastasis in patients with ovarian cancer].
19891 citationsauthor #3
20 Association of human papillomavirus types with histological types of cervical carcinomas.
19890 citationsauthor #3
511. The Significance of Serum Specific IgA Antibody to Chlamydia Trachomatis in the Diagnosis and Treatment of Female Genital Tract Chlamydial Infection
19880 citationsauthor #3
83. Detection of Human Papillomavirus (HPV) Types 16 and 18 Infection Using Filter-in-situ Hybridization
19880 citationsauthor #1
[Evaluation of anti-Chlamydia trachomatis IgA antibody in the treatment of female genital tract chlamydial infections].
19872 citationsauthor #2
22. Study of the Physical State of Human Papillomaviruses in Cervical Cancer and Condylomatous Lesions
19860 citationsauthor #4

TIMELINE

1986 0 citations

1987 2 citations

1988 0 citations

1989 1 citations

1990 14 citations

1991 7 citations

1992 2 citations

1996 154 citations

1997 197 citations

2002 15 citations

2004 130 citations

2008 7 citations

2009 58 citations

2010 185 citations

2011 8 citations

2012 42 citations

2013 186 citations

2014 88 citations

2015 115 citations

2016 249 citations

2017 36 citations

2018 177 citations

2019 3 citations

2020 191 citations

2022 19 citations

2023 4 citations

2024 6 citations

COAUTHOR MAP

CONCEPT FOOTPRINT